Trimethylamine N-oxide and kidney diseases: what do we know?

J Bras Nefrol. 2023 Dec 1:S0101-28002023005046502. doi: 10.1590/2175-8239-JBN-2023-0065en. Online ahead of print.ABSTRACTIn the human gut, there is a metabolically active microbiome whose metabolic products reach various organs and are used in the physiological activities of the body. When dysbiosis of intestinal microbial homeostasis occurs, pathogenic metabolites may increase and one of them is trimethyl amine-N-oxide (TMAO). TMAO is thought to have a role in the pathogenesis of insulin resistance, diabetes, hyperlipidemia, atherosclerotic heart diseases, and cerebrovascular events. TMAO level is also associated with renal inflammation, fibrosis, acute kidney injury, diabetic kidney disease, and chronic kidney disease. In this review, the effect of TMAO on various kidney diseases is discussed.PMID:38039494 | DOI:10.1590/2175-8239-JBN-2023-0065en
Source: Jornal Brasileiro de Nefrologia - Category: Urology & Nephrology Authors: Source Type: research